Cancer Biology & Medicine最新文献

{"title":"Erratum to Flotillin1 promotes EMT of human small cell lung cancer via TGF-β signaling pathway.","authors":"Lianmei Zhao, Jie Li, Yueping Liu, Wei Zhou, Yanan Shan, Xinyi Fan, Xinliang Zhou, Baoen Shan, Yongmei Song, Qimin Zhan","doi":"10.20892/j.issn.2095-3941.2026.0738","DOIUrl":"https://doi.org/10.20892/j.issn.2095-3941.2026.0738","url":null,"abstract":"","PeriodicalId":9611,"journal":{"name":"Cancer Biology & Medicine","volume":" ","pages":""},"PeriodicalIF":12.4,"publicationDate":"2026-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149191401","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A bispecific EGFR × HER3 antibody-drug conjugate for later-line recurrent or metastatic nasopharyngeal carcinoma: insights from BL-B01D1-303.","authors":"Huaqiang Zhou, Jiayi Shen, Jiaqing Liu, Li Zhang, Yunpeng Yang","doi":"10.20892/j.issn.2095-3941.2026.0336","DOIUrl":"https://doi.org/10.20892/j.issn.2095-3941.2026.0336","url":null,"abstract":"","PeriodicalId":9611,"journal":{"name":"Cancer Biology & Medicine","volume":" ","pages":""},"PeriodicalIF":12.4,"publicationDate":"2026-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149073220","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efbemalenograstim alfa as prophylaxis for chemotherapy-induced neutropenia in patients with non-small-cell lung cancer: a randomized, multicenter, phase II trial.","authors":"Mengjie Li, Caixia Liu, Fengming Ran, Haitao Lan, Jun Ge, Zheng Zhao, Chuangzhou Rao, Wei Zheng, Xiaoyong Tang, Tianhui Gao, Yong Mao, Wei Cui, Zhengguo Li, Dingzhi Huang","doi":"10.20892/j.issn.2095-3941.2026.0311","DOIUrl":"https://doi.org/10.20892/j.issn.2095-3941.2026.0311","url":null,"abstract":"<p><strong>Objective: </strong>Primary prophylaxis with granulocyte colony-stimulating factor (G-CSF) is recommended for patients receiving chemotherapy with a high risk of febrile neutropenia (FN), but its use remains suboptimal in patients receiving intermediate-risk regimens who have additional risk factors, for whom secondary prophylaxis (SPx) is commonly used despite limited prospective evidence comparing the two approaches. This study evaluated efbemalenograstim alfa (EFBGα), a novel Fc fusion G-CSF, as primary or secondary prophylaxis for chemotherapy-induced neutropenia (CIN) in patients with non-small-cell lung cancer (NSCLC) receiving intermediate-risk FN regimens who have additional risk factors.</p><p><strong>Methods: </strong>This multicenter, randomized phase II trial enrolled chemotherapy-naïve patients with stage IIIB/IV NSCLC scheduled for platinum-taxane chemotherapy. Patients were randomized 2:1 to either primary prophylaxis (EFBGα 20 mg at 48 ± 4 h after each cycle) or secondary prophylaxis (given only after grade 3-4 neutropenia). The primary endpoint was the cycle 1 incidence of grade 3-4 neutropenia.</p><p><strong>Results: </strong>A total of 102 patients were enrolled between February 2024 and December 2025, of whom 96 were included in the analysis: 63 in the primary prophylaxis group and 33 in the secondary prophylaxis group. In cycle 1, the incidence of grade 3-4 neutropenia was lower with primary prophylaxis than with secondary prophylaxis [20.6%, 95% confidence interval (CI) 11.5%-32.7% <i>vs.</i> 57.6%, 95% CI 39.2%-74.5%; risk difference -36.9%, 95% CI -52.4% to -16.1%; <i>P</i> < 0.001]. The median duration of grade 3-4 neutropenia was comparable between the groups (<i>P</i> = 0.144). Cycle 1 FN incidence was 1.6% in the primary and 6.1% in the secondary prophylaxis group. Treatment-related adverse events were mostly grade 1-2, with pain-related events (7.0%) being the most common.</p><p><strong>Conclusions: </strong>EFBGα exhibited promising efficacy and tolerability for CIN prophylaxis in patients with NSCLC and additional risk factors who are receiving intermediate-risk chemotherapy (IRC). The results support its use in both primary and secondary prophylactic strategies, and earlier initiation was associated with better CIN control.</p>","PeriodicalId":9611,"journal":{"name":"Cancer Biology & Medicine","volume":" ","pages":""},"PeriodicalIF":12.4,"publicationDate":"2026-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149023901","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Revisiting the immunosuppressive microenvironment in hepatocellular carcinoma: a functional taxonomy of immune cells and therapeutic targeting.","authors":"Jiaqian Zhang, Siwen Li, Xianglong Ma, Xiaomin You, Huaping Li, Chen Chen, Daiming Fan, Yongzhan Nie, Kaichun Wu, Wenjie Huang, Limin Xia","doi":"10.20892/j.issn.2095-3941.2026.0154","DOIUrl":"https://doi.org/10.20892/j.issn.2095-3941.2026.0154","url":null,"abstract":"<p><p>Despite transformative success in other solid tumors, immunotherapy has encountered a formidable barrier in hepatocellular carcinoma (HCC), a profoundly immunosuppressive tumor microenvironment (TME) that is predominantly \"cold\" and also exhibits remarkable heterogeneity across patients. This inter-patient variability in the immune context leads to different responses to treatment, limits clinical efficacy, and highlights the critical need for a deeper, systems-level understanding of the HCC immune landscape. This review provides an integrated and conceptual analysis of the HCC immune landscape. It delineates the mechanistic drivers underlying immune suppression, summarizes current immune-based classification frameworks, and dissects the context-dependent functions of key immune cell populations in tumor progression. Furthermore, this review surveys established TME-targeting therapies comprising primarily immune checkpoint blockade strategies and their clinically validated combinations, and highlights emerging agents and concepts under preclinical and early clinical development. By integrating mechanistic insights with immune classification and therapeutic advances, this review aims to provide a unifying framework to inform the rational design of next-generation immunotherapies for HCC.</p>","PeriodicalId":9611,"journal":{"name":"Cancer Biology & Medicine","volume":" ","pages":""},"PeriodicalIF":12.4,"publicationDate":"2026-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148975822","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Migrasome-propagated ITGβ3-TGFβ1 circuit orchestrates breast cancer brain metastasis by reprogramming the microglial niche.","authors":"Song Wang, Xinmiao Xian, Guohao Gu, Jianran Guo, Meng An, Dongbao Li, Qian Wang, Xuefang Huang, Shen Chen, Wei Zhang, Bo Fu","doi":"10.20892/j.issn.2095-3941.2025.0803","DOIUrl":"https://doi.org/10.20892/j.issn.2095-3941.2025.0803","url":null,"abstract":"<p><strong>Objective: </strong>The dismal prognosis of breast cancer brain metastasis (BCBM) is attributed to a maladapted tumor microenvironment. This study was aimed at deciphering the role of novel intercellular communicators, tumor-derived migrasomes, in driving BCBM progression, with a focus on their ability to co-opt brain-resident microglia.</p><p><strong>Methods: </strong>Migrasomes were isolated and characterized from brain-tropic (231-BR; Mig-BCBM) and parental breast cancer cells, patient-derived metastatic breast cancer tissues, and mice BCBM tissues. The functional axis was delineated through an integrative approach encompassing proteomics, <i>in vitro</i> co-culture systems, <i>in vivo</i> brain colonization assays, genetic perturbations, and a pharmacological intervention with the clinical-stage TGFβR1 inhibitor galunisertib.</p><p><strong>Results: </strong>Mig-BCBM were internalized by microglia, thus triggering their repolarization to a pro-tumorigenic, M2-like state, both <i>in vitro</i> and <i>in vivo</i>. Proteomic profiling identified integrin β3 (ITGβ3) as a key regulator selectively packaged into Mig-BCBM. Mechanistically, migrasomal ITGβ3 activated the PI3K/AKT pathway in microglia, thus driving M2 polarization. These reprogrammed microglia secreted high levels of TGFβ1, which in turn fostered a metastatic niche by inducing Smad2/3-dependent epithelial-mesenchymal transition (EMT) in tumor cells. Crucially, we uncovered a self-amplifying feedforward loop in which microglial-derived TGFβ1 transcriptionally upregulates TSPAN4 <i>via</i> EGR1 in cancer cells, thus enhancing migrasome biogenesis and subsequent ITGβ3 loading. Disrupting this loop with galunisertib potently inhibited BCBM outgrowth and colonization <i>in vivo</i>, without systemic toxicity.</p><p><strong>Conclusions: </strong>This study identified a targetable circuit in BCBM wherein tumor-derived migrasomes, <i>via</i> ITGβ3, engage microglia in a TGFβ1-centered crosstalk. Because this self-reinforcing ITGβ3-TGFβ1 axis sustains the pro-metastatic niche, its disruption might provide a rational therapeutic strategy.</p>","PeriodicalId":9611,"journal":{"name":"Cancer Biology & Medicine","volume":" ","pages":""},"PeriodicalIF":12.4,"publicationDate":"2026-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148918199","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Erratum to From residual risk to precision intervention: the evolving role of minimal residual disease in breast cancer management.","authors":"Junnan Xu, Kun Fang, Xiaoxi Li, Li Han, Shulan Sun, Tao Sun","doi":"10.20892/j.issn.2095-3941.2026.0704","DOIUrl":"https://doi.org/10.20892/j.issn.2095-3941.2026.0704","url":null,"abstract":"","PeriodicalId":9611,"journal":{"name":"Cancer Biology & Medicine","volume":" ","pages":""},"PeriodicalIF":12.4,"publicationDate":"2026-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148918246","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"cGAS-STING pathway activation drives the cold-to-hot tumor transition and sensitizes immunotherapy.","authors":"Xinru Zhao, Shuai Meng, Hanzeng Cheng, Haixia Yu, Meiting Rong, Chao Zhang, Cien Qiu, Jie Zhang, Chunnuan Wu, Wenxia Zhao","doi":"10.20892/j.issn.2095-3941.2026.0058","DOIUrl":"10.20892/j.issn.2095-3941.2026.0058","url":null,"abstract":"<p><p>The cyclic GMP-AMP synthase-stimulator of interferon genes (cGAS-STING) pathway is a central sensor of innate immunity that plays critical roles in recognizing cytosolic DNA and initiating antitumor immune responses. However, this pathway exhibits extensive spatiotemporal duality and context dependency in tumor regulation. In recent years, modulating this pathway to convert immunologically \"cold\" tumors into immunologically \"hot,\" inflamed tumors has emerged as a cutting-edge strategy to reverse resistance to immune checkpoint inhibitors (ICIs). This review outlines the molecular mechanisms underlying the activation and regulation of the cGAS-STING pathway, with emphasis on its complex role in orchestrating the tumor immune phenotypic switch. A nuanced analysis of the pathway's duality distinguishes between acute immunostimulatory activation and chronic, pro-tumorigenic inflammation driven by chromosomal instability (CIN). Furthermore, current evidence regarding direct and indirect T-cell modulation, as well as pathway-mediated remodeling of the tumor microenvironment (TME) across diverse malignancies, is discussed in detail. Crucially, the current bottlenecks in clinical translation are described, including evaluation of the failure of first-generation agonists and the promise of next-generation delivery platforms such as antibody-drug conjugates (ADCs) and nanoparticle systems. Finally, a novel strategic framework is proposed involving mapping of specific STING-targeted modalities to distinct TME phenotypes, such as immune-desert, immune-excluded, and exhausted-inflamed states. A detailed understanding of the cGAS-STING axis has substantial value in providing theoretical guidance and supporting clinical translation in the development of next-generation combination immunotherapies, as well as broadening the patient population benefiting from clinical interventions.</p>","PeriodicalId":9611,"journal":{"name":"Cancer Biology & Medicine","volume":" ","pages":""},"PeriodicalIF":12.4,"publicationDate":"2026-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13617945/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148761623","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rethinking nasopharyngeal carcinoma management: toward a low-toxicity, highly effective regimen with favorable tolerability and quality of life.","authors":"Yingni Zhang, Chunxian Ou, Cheng Xu","doi":"10.20892/j.issn.2095-3941.2026.0316","DOIUrl":"https://doi.org/10.20892/j.issn.2095-3941.2026.0316","url":null,"abstract":"","PeriodicalId":9611,"journal":{"name":"Cancer Biology & Medicine","volume":" ","pages":""},"PeriodicalIF":12.4,"publicationDate":"2026-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148705480","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Global landscape and temporal trends in lifetime risk of colorectal cancer in 185 countries: a population-based study.","authors":"Li Li, Kexin Sun, Xiang Li, Yifei Yao, Hengxi Li, Shaoming Wang, Wanqing Chen, Rongshou Zheng","doi":"10.20892/j.issn.2095-3941.2025.0851","DOIUrl":"10.20892/j.issn.2095-3941.2025.0851","url":null,"abstract":"<p><strong>Objective: </strong>Colorectal cancer (CRC) is the third most common cancer and the second leading cause of cancer-related mortality worldwide. This study was aimed at estimating regional and national variations in lifetime CRC risk worldwide.</p><p><strong>Methods: </strong>CRC data were extracted from GLOBOCAN 2022, including 185 countries, and population and all-cause mortality data were sourced from the United Nations. The world was divided into 20 geographical regions and categorized by Human Development Index (HDI). Lifetime CRC risk was estimated with the life table method, adjusted for multiple primary cancers.</p><p><strong>Results: </strong>In 2022, the lifetime risks of developing and dying from CRC were 2.69% [95% confidence interval (CI): 2.68-2.70] and 1.39% (95% CI: 1.39-1.40), respectively. Men had a higher risk of colon cancer than rectal cancer, and higher CRC risk than women. Lifetime risk varied by region and HDI: regions with very high, high, moderate, and low HDI had incidence risks of 5.17%, 2.75%, 0.72%, and 0.57%, respectively, and mortality risks of 2.48%, 1.50%, 0.44%, and 0.41%, respectively. Australia/New Zealand had the highest incidence risk (7.41%, 95% CI: 7.30-7.52), and Northern Europe the highest mortality risk (3.28%, 95% CI: 3.24-3.32). Risks were stable before 40 years of age, peaked in middle age, and declined after 70 years of age. Temporally, Thailand had the highest increasing trend in lifetime risk, whereas the United States and Austria showed a decreasing trend.</p><p><strong>Conclusions: </strong>Lifetime CRC risk differs by subtype, sex, HDI, and geography, and residual risk gradually decreases with age. Targeted primary prevention strategies should be implemented in various countries and regions to mitigate CRC burden.</p>","PeriodicalId":9611,"journal":{"name":"Cancer Biology & Medicine","volume":"23 7","pages":""},"PeriodicalIF":12.4,"publicationDate":"2026-08-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13449712/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148683355","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Anogenital human papillomavirus infection patterns by anatomical site and sexual orientation in Chinese men: a national multi-center study.","authors":"Shangying Hu, Huan Yang, Jinyu Zhang, Hongyang Yu, Yutong Li, Douhong Li, Qiaoyun Du, Yu Cui, Xuelian Zhao, Yongjiang Liu, Fanghui Zhao","doi":"10.20892/j.issn.2095-3941.2026.0129","DOIUrl":"10.20892/j.issn.2095-3941.2026.0129","url":null,"abstract":"","PeriodicalId":9611,"journal":{"name":"Cancer Biology & Medicine","volume":" ","pages":""},"PeriodicalIF":12.4,"publicationDate":"2026-08-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13449710/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148677120","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}